Pentostatin, Cyclophosphamide and Rituximab Followed by Alemtuzumab for Relapsed or Refractory Chronic Lymphocytic Leukemia: A Phase 2 Trial of the ECOG-ACRIN Cancer Research Group (E2903)
Clicks: 265
ID: 269696
2019
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
30.0
/100
265 views
36 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #4 of 25 articles by views in acta haematologica
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) may benefit from salvage chemoimmunotherapy (CIT). To explore further the use of CIT in the pre-novel agent era, ECOG-ACRIN undertook a phase 2 trial (E2903) for R/R CLL utilizing ...
Abstract Quality Issue:
This abstract appears to be incomplete or contains metadata (39 words).
Try re-searching for a better abstract.
| Reference Key |
tallman2019actapentostatin,
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Sanford Kempin, Zhuoxin Sun, Neil E. Kay, Elisabeth M. Paietta, Joseph J. Mazza, Rhett P. Ketterling, Olga Frankfurt, David F. Claxton, Joel N. Saltzman, Gordan Srkalovic, Natalie S. Callander, Gerald Gross, Martin S Tallman;Sanford Kempin;Zhuoxin Sun;Neil E. Kay;Elisabeth M. Paietta;Joseph J. Mazza;Rhett P. Ketterling;Olga Frankfurt;David F. Claxton;Joel N. Saltzman;Gordan Srkalovic;Natalie S. Callander;Gerald Gross;Martin S Tallman; |
| Journal | acta haematologica |
| Year | 2019 |
| DOI |
10.1159/000500164
|
| URL | |
| Keywords |
|
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.